Drug Profile
RG 7827
Alternative Names: FAP-4-1BBL; FAP-4-1BBL FP; RG-7827; RO-7122290Latest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Roche Innovation Center Zurich
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD137 antigen agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer; Urogenital cancer
- Phase I Solid tumours
Most Recent Events
- 27 Apr 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) is ongoing in Spain (Parenteral) (Roche pipeline, April 2022)
- 27 Apr 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) is ongoing in Spain (Parenteral) (Roche pipeline, April 2022)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Spain (Parenteral)